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Overview
General topic:
Supply chain models and their analysis for autologous cell
therapy manufacturing and distribution
Objectives:
 Safety: Safe cell therapy products
 Efficacy: Cell therapy products with high level of efficacy
 Cost: Reduce total manufacturing logistics costs and cost to the
patient
 Risk: Reduce the risk of patient morbidity and mortality
(reduce fulfillment time and fulfillment time variability)
 Patient access: Increase patient access through network design
Center for Cell Manufacturing Technologies
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Overview
Exemplar: CAR-T cells
Partners: Georgia Tech, Univ of Wisconsin-Madison, Univ of
Pennsylvania
Deliverable: simulation/optimization-based decision support
tools for “WHAT-IF” analysis
 Single manufacturing facility (building block)
 Supply chain network: facilities, suppliers, and clinics
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Alternative supply chain design strategies
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Issues addressed & to be addressed
 Network design:
 How many facilities, facility locations, determining what
facilities provide service to which clinics
 Reagent supply disruption analysis
 Supply chain operations & patient health:
 Specimen queuing policy (FIFO, priority)
 Impact on manufacturing and QC sub-processes
 Inventory policy
 Number of bioreactors
 Number of operators
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Applications of the Simulation Toolset
 Applications

o Evaluate supply chain design models for cell therapy manufacturing and distribution
o Simulate unexpected events, such as reagent supply disruptions, and estimate the risks
associated with these events
o Assess risk mitigation strategies

 Representative strategies to mitigate unexpected supply disruptions
o Buffer stock of reagents
o Multiple suppliers for key reagents
o Capability of rapidly ramping up supplies and production
o Trans-shipment of orders, bioreactors, reagents, etc.

 Decisions that can be supported by the simulation toolset
o Time to restore the original steady state
o Average increased queue time
o Order reject rate
o Implementation cost

Center for Cell Manufacturing Technologies

6

How base stock level influences cancelled rate
 Cancelled rate versus base stock
level
 Run 10 simulations at 6 different
base stock levels
 Record average cancelled rate at
T=1000
 as we increase base stock level,
cancelled rate decreases
[# of Bioreactor fixed at 10, fastest
lead time fixed at 20]
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Supply Disruption Case Study
 Case study motivation
o Visit to UPenn revealed another challenge – supply disruption
o Small number of suppliers for some key reagents
o Switching suppliers may need FDA re-approval => barrier to supplier risk
mitigation
 Case study description
o Single reagent
o Two month disruption in reagent supply
o Objectives: to understand the impact of supply disruptions and how to
recover from them
 Compare three scenarios
o Single supplier, single production facility – multiple cases
o Two suppliers, one production facility
o Two suppliers, two production facilities that allow transferring orders
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Single facility, no disruption case

 Patients per year: 250
 Bioreactors: 10
 Operators: 6
 Stationary operating condition:
base stock level = 100, days 1-500
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60-day disruption case

 Patients per year: 250
 Bioreactors: 10
 Operators: 6
 Base stock level = 100, days 1-200
 Base stock level = 0, days 201-260
 Base stock level = 100, days 261-500
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60-day disruption: bioreactors: 11, operators: 6
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60-day disruption: bioreactors: 10, operators: 7
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60-day disruption: bioreactors: 11, operators: 7
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60-day disruption: bioreactors: 12, operators: 7
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60-day disruption: bioreactors: 15, operators: 9
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60-day disruption: bioreactors: 20, operators: 12
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Network design for risk mitigation
Simulation model used to evaluate two network designs for mitigating
supply disruption risks
Supplier 2
Facility 1
Supplier 2
Facility 1

Supplier 1
(100% disruption)

Supplier 1
(100% disruption)

Facility 2

50% order transfer
after disruption

Adding one reagent supplier
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Evaluation of risk-mitigation strategies
Queue Time

Effect

Order Transshipment

Multiple Supplier

Scenario
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Patient health based manufacturing
 Risks:
 Patient may not survive before therapy becomes available
 Therapy may not be effective
 Therapy may be contaminated
 For a given patient, what is the best ‘balance’ of these risks in order
to minimize total mortality risk? When should manufacturing and
QC processes be accelerated and by how much?
 What R&D investments would have the greatest impact in reducing
these risks?
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Summary
 Disruption recovery can require surge capability that is not needed
in steady state operations
 Surge capability occurs at several levels: reagent supply,
bioreactors, skilled staff
 Network designs that allow for transshipment of reagents and
specimens can pool and hence mitigate the risk of a supplier
disruption
 Next steps – patient health-based manufacturing
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